Vaxcyte (NASDAQ:PCVX) CAO Sells $146,475.00 in Stock

Vaxcyte, Inc. (NASDAQ:PCVX) CAO Elvia Cowan sold 2,500 shares of the company’s stock in a transaction on Wednesday, March 11th. The stock was sold at an average price of $58.59, for a total value of $146,475.00. Following the transaction, the chief accounting officer owned 30,867 shares of the company’s stock, valued at approximately $1,808,497.53. The trade was a 7.49% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Elvia Cowan also recently made the following trade(s):

• On Tuesday, December 23rd, Elvia Cowan sold 11,623 shares of Vaxcyte stock. The shares were sold at an average price of $47.92, for a total value of $556,974.16.

Vaxcyte Stock Performance

Shares of PCVX opened at $54.58 on Friday. Vaxcyte, Inc. has a 1 year low of $27.66 and a 1 year high of $76.61. The company has a market cap of $7.86 billion, a price-to-earnings ratio of -9.71 and a beta of 1.31. The firm has a fifty day moving average of $54.08 and a 200-day moving average of $45.80.

Vaxcyte (NASDAQ:PCVX) last released its quarterly earnings results on Tuesday, February 24th. The company reported ($1.80) EPS for the quarter, missing the consensus estimate of ($1.46) by ($0.34). During the same period last year, the company posted ($1.12) EPS. Analysts predict that Vaxcyte, Inc. will post -4.21 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. Guggenheim restated a “buy” rating and issued a $116.00 price target on shares of Vaxcyte in a research note on Monday, February 2nd. Needham & Company LLC boosted their price objective on Vaxcyte from $90.00 to $110.00 and gave the stock a “buy” rating in a research report on Wednesday, January 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Vaxcyte in a report on Friday, January 9th. Jefferies Financial Group restated a “buy” rating on shares of Vaxcyte in a research report on Tuesday. Finally, BTIG Research lifted their target price on Vaxcyte from $85.00 to $89.00 and gave the company a “buy” rating in a research note on Wednesday, February 25th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $94.50.

Institutional Trading of Vaxcyte

Institutional investors have recently made changes to their positions in the stock. Smartleaf Asset Management LLC boosted its holdings in shares of Vaxcyte by 156.2% in the fourth quarter. Smartleaf Asset Management LLC now owns 597 shares of the company’s stock valued at $27,000 after acquiring an additional 364 shares in the last quarter. Caitong International Asset Management Co. Ltd raised its holdings in Vaxcyte by 1,463.4% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 641 shares of the company’s stock worth $30,000 after purchasing an additional 600 shares in the last quarter. EverSource Wealth Advisors LLC lifted its position in Vaxcyte by 33.0% in the fourth quarter. EverSource Wealth Advisors LLC now owns 741 shares of the company’s stock worth $34,000 after purchasing an additional 184 shares during the period. Allworth Financial LP boosted its holdings in Vaxcyte by 148.9% during the third quarter. Allworth Financial LP now owns 1,222 shares of the company’s stock worth $44,000 after buying an additional 731 shares in the last quarter. Finally, Aster Capital Management DIFC Ltd acquired a new position in Vaxcyte in the third quarter worth approximately $45,000. 96.78% of the stock is owned by institutional investors and hedge funds.

Vaxcyte Company Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.